INTRODUCTION
Apoptosis, or programmed cell death, is an essential component for embryogenesis and homeostasis. Dysregulation of apoptosis is associated with many diseases such as cancer, autoimmunity, and neurodegenerative disorders (1) . Many anticancer therapies exert their therapeutic effects by inducing apoptosis in tumor cells. A suitable in ViVo marker for noninvasive imaging of apoptosis would be useful for both clinical care and drug development.
One of the early characteristics of apoptosis is the externalization of phosphatidylserine (PS) molecules on cell membranes, which promotes recognition and phagocytic removal (2, 3) . In culture, once apoptosis is triggered, the PS externalization begins to occur within one hour (2) . Annexin V, a 36 kDa endogenous cytoplasmic protein, binds with high affinity (K d ∼10 nM) to membrane-bound PS in a Ca 2+ -dependent manner (4) . Annexin V staining has been a standard practice for the assessment of apoptosis in Vitro for the past decade. More recently, radiolabeled annexin V has been actively investigated to image cell death (5) (6) (7) (8) . Tc-labeled annexin V showed promising results in early clinical SPECT studies (9) (10) (11) , but its low sensitivity has limited its broader application. To take advantage of the higher resolution and more accurate quantification of PET, labeling annexin V with short half-life positron-emitters such as 18 F is of particular interest. We (12) and others (13, 14) have reported the labeling of wild-type annexin V with N-succinimidyl-4- showed increased uptake in rat liver proportional to apoptosis after apoptosis was chemically induced (15) . The rapid blood clearance and urinary excretion of [ 18 F]FAN suggest its potential as a PET imaging agent. This radiotracer, however, has its own disadvantages. The predominant renal clearance increases the radiation burden to the kidneys and bladder, and a patient would have to be catheterized if the diagnostic area of interest were in the abdomen (15 An alternative strategy to label proteins involves targeting the free thiol groups that are present only in cysteine residues. Thiol reactive agents such as N-substituted maleimides and iodoacetamide can be used to modify proteins at cysteines at specific sites (17) (18) (19) (20) . Annexin V-128 is a mutated form of annexin V containing only one cysteine. The initiator Met at position one is deleted and a six amino acid extension containing one cysteine is added at the N-terminus. The N-terminus does not play a role in the binding activity of annexin V and so this modification does not change the binding affinity of annexin V-128 for PS. Site-specific labeled (with 99m Tc) annexin V-128 derivatives showed twice as much in ViVo apoptosis-specific uptake in rat liver models as did amine-derivatized forms of annexin V (16) . A previous approach to label thiol-containing molecules with N- [4-[(4 
MATERIALS AND METHODS
General. All reagents and solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI) as reagent grade and were used without purification unless otherwise noted. The labeling precursor, 4-trimethylammoniumbenzaldehyde triflate 1, was prepared as described by Haka et al. (24) and stored in a sealed vial over desiccant in the refrigerator. The coupling precursor, N- [4-(aminooxy) Preparation of Annexin V-128. Annexin V-128 (∼2 mg/ mL in 20 mM HEPES sodium, 100 mM NaCl, pH 7.4) was prepared and purified as described (26) . The protein was reduced with 1 mM dithiothreitol (DTT) for 15 min at 37°C and then applied to a Sephadex G-25 column equilibrated with deoxygenated buffer (20 mM HEPES-sodium, 100 mM NaCl, pH 7.4) to remove the reductant. Protein concentration was measured by absorbance at 280 nm and the reduced protein was used for labeling within 6 h. F -on the cartridge was then eluted with 1.4 mg K 2 CO 3 in 0.5 mL 1:1 (v:v) acetonitrile/water solution into the reaction vessel of the FX FN box. A solution of 7.5 mg Kryptofix[2,2,2] in 2 mL anhydrous acetonitrile was then added to the same reaction vessel and the whole mixture was azeotropically evaporated to dryness under heat and reduced pressure. A solution of 4-5 mg 4-trimethylammoniumbenzaldehyde triflate 1 in 1 mL anhydrous acetonitrile was then pushed into the reactor, pressurized (∼200 mbar), and heated at 100°C. After 15 min, the reaction vessel was cooled to r.t. before 8-9 mg 3 in 1.5 mL methanol was added. After stirring at r.t. for 15 min, the mixture was slowly evaporated to <0.5 mL with heat (50°C) under vacuum. After cooling to r.t., 1.5 mL of 45% ethanol in water (v:v) was added to the reaction vessel and the whole mixture was transferred to the HPLC loop. Semipreparative HPLC was performed with a C18 column (Phenomenex Prodigy ODS(3), 5 µm, 250 × 10 mm) eluted with 45% ethanol/water (v:v) at 3 mL/min and 50°C
. The chemically and radiochemically (>99%) pure fraction containing [
18 F]FBABM was collected (∼12 mL; t R ∼ 38-40 min). The chemical and radiochemical purity was assessed with a C18 analytical HPLC column (Phenomenex Inertisil ODS-3, 100 × 2.1 mm, 5 µm, eluted with 55% methanol/water (v:v) at 0.3 mL/min flow rate and 40°C with in-line mass detection.
Labeling of Annexin V-128 with [ 18 F]FBABM. Purified [
18 F]FBABM from the previous step (∼12 mL) was diluted with water (∼50 mL) and passed through a Waters C18 SepPak that had been preconditioned with 5 mL ethanol and 5 mL water. The SepPak was washed with additional 10 mL water and the excess water was expelled with a push of air. 2 mL of ether was then pushed through the SepPak to elute the product into a clean 5 mL glass test tube. The ether phase of the biphase mixture was drawn out and transferred into a clean 5 mL BD Vacutainer test tube. The ether was then removed by evaporation under a gentle flow of argon at 50°C. After cooling to r.t., approximately 0.7 mg freshly prepared annexin V-128 in 0.5 mL buffer (20 mM HEPES, 100 mM NaCl, pH 7.4) was carefully added to the residual film and incubated for 15 min with periodic gentle agitation. Labeled [ 18 F]FAN-128 (diluted to a final concentration of 1 nM) in buffer (100 mM NaCl, 50 mM Hepes-Na, pH 7.4, 0.02% NaN 3 , 1 mg/ml BSA) and CaCl 2 at precise concentrations (between 0 and 3 mM) were prepared. The mixtures were incubated for 10 min. at r.t. After centrifugation, the supernatant was discarded. 18 F]FBABM was labor-intensive, with a two-pot setup and a C18 SepPak purification step in between. Second, although the labeling of GSH gave good yield (70% decay corrected), the yield in labeling larger biomolecules such as 5′-S-ODN (5% decay corrected) was low. The concentrations of the GSH or the 5′-S-ODN in these reactions were 6 mM and 0.1 mM, respectively. The radiochemical yield of radiolabeled peptides/ proteins or other biomolecules via prosthetic groups typically decreases as the concentration of the biomolecule decreases. For an even larger molecule such as annexin V-128, which is usually obtained in ∼30 µM concentration, the radiochemical yield might be even lower than 5%. Indeed, our initial attempts to label annexin V-128 with [ 18 F]FBABM synthesized by closely following the literature procedure (12) (24, 25) . We chose the lower boiling acetonitrile because it could be easily removed by evaporation. Compared with DMSO, the use of acetonitrile did not compromise the yield of [ (Table 1) . Similar yields were obtained while the same amounts of precursors were used. A smaller amount of precursors resulted in decreased yields of 2. Using 4 mg triflate precursor struck a balance between reasonably high yield and acceptably lower quantity of material introduced into the system. Compared to the Toyokuni report (21) , the yield of the coupling reaction dropped from ∼70% to ∼40% (calculated from the yield of the first step and the overall yield), but the advantage of easier production of this radiotracer outweighed this reduction of yield. It is important to note that, because FBA is a volatile compound at elevated temperature, it is crucial to cool the reaction mixture to r.t. before opening the reaction vessel to add the coupling precursor.
The critical factor for optimal protein labeling with [ 18 F]F-BABM is the chemical purity of the product. We suspected that a maleimide side product was present that would compete with [ 18 F]FBABM for reaction with thiol groups. HPLC-MS was used to identify this major contaminant as N- [4- [(4-dimethylaminobenzylidene)aminooxy]butyl]maleimide (4) (estimated >100 µg from a typical run described above) derived from the 4-dimethylaminobenzaldehyde formed inevitably during the initial nucleophilic fluorination step (Scheme 2). In a typical run, about 300 µg 4-dimethylaminobenzaldehyde was detected after this first step. The identity and quantity was determined by HPLC-MS analysis, in comparison to an authentic sample. Our initial attempt to label annexin V-128 with [ 18 F]FBABM containing 4 gave no yield, presumably due to a competition for the single thiol group by the vast molar excess of the alternative maleimide contaminant 4. In a typical labeling reaction, the molar ratio of FBABM to annexin V-128 (generally 0.6 mg was used) c Determined from radio-HPLC chromatograms of the crude product. Data represent an average of 3 runs. was approximately 1:1, whereas that of 4 was greater than 20:1. Attempts to remove the undesired 4-dimethylaminobenzaldehyde after the first step with a C18 SepPak were unsuccessful. The removal of 4 from the final product [ 18 F]FBABM proved to be challenging. The calculated log P values for FBABM and 4 are 1.91 and 1.85, respectively (Molinspiration program: http:// www.molinspiration.com/cgi-bin/properties). The two compounds coeluted using the HPLC method from the literature (21). We developed a useful separation by using Phenomenex Prodigy ODS(3) 5 µm 250 × 10 mm column. At 50°C and 45% ethanol/ water as the eluent at 3 mL/min, 4 was completely removed from [ Annexin V-128 (26) contains one cysteine in its N-terminus. The single naturally occurring cysteine residue in its interior domain has been mutated to a serine in order to eliminate the possibility of modification by thiol-reactive prosthetic conjugating agents. Annexin V-128 is freshly reduced immediately prior to each labeling study with DTT to ensure that the free thiol is fully accessible. The protein is purified of excess DTT by eluting through a Sephadex column.
The purified [ As a negative control, we repeated the reaction under the same condition using wild-type annexin V instead of mutated annexin V-128. Wild-type annexin V has one internal cysteine but it does not have a free thiol group on its N-terminus. In this reaction, the yield of 18 Figure 2 . The binding affinity was measured by determining EC 50 and slope from this experimental titration curve (22) . The negative log of the binding constant, pK, is equal to -(n log 10 EC 50 + log 10 [membrane]), where n is the number of Ca 2+ ions interacting with each annexin V molecule, the EC 50 is the molarity of Ca 2+ at which cell binding is half of the maximal value, and [membrane] is the concentration of annexin V-binding sites in the assay (16 
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